News | Radiopharmaceuticals and Tracers | November 03, 2015

Minomic to Begin First-In-Human Trial of Novel Prostate Cancer Imaging Agent

Australian trial with 12 patients to begin in first quarter of 2016

Minomic, MUH, first-in-human trial, novel prostate cancer imaging agent, MIL-38, Australia

November 3, 2015 — Australian immuno-oncology company Minomic International Ltd has struck an agreement to launch the first human study of its novel monoclonal antibody technology as an imaging agent to detect prostate, pancreatic and bladder cancers.

The company has signed a Heads of Agreement with Macquarie University Hospital (MUH) and Macquarie Medical Imaging (MMI) to examine the use of Minomic’s proprietary MIL-38 monoclonal antibody — already a centrepiece of its MiCheck novel prostate cancer diagnostic screening technology — as a new tool to enable better detection and targeted treatment of prostate and other cancers.

This first-in-human study will begin recruiting the first of 12 patients in Q1 2016, with the study expected to run during 2016.

Under study protocols, a team of investigators led by Profs. Howard Gurney and David Gillatt from MUH and Kevin Ho-Shon, Ph.D., of MMI, will examine a chimeric version of Minomic’s MIL-38 antibody conjugated with 67Gallium (MILGa) to image cancer metastases following ethics approval.

Investigators will evaluate the technology for safety, sensitivity and specificity of MILGa in these patients.

“We have had highly encouraging results in our preclinical animal studies. By formulating a chimeric version of the MIL-38 antibody, we are able to ensure a patient’s own immune system does not recognise our antibody as foreign. Our antibody will then seek out the target, which is a protein found on cancer cells. We will attach a payload to our antibody – either an existing drug or radiotherapy – so that our technology can be used to directly deliver the appropriate therapy to the tumour cell target for maximum impact. Following successful targeting to tumour metastases in this study the company intends to undertake a therapeutic trial,” said Minomic CEO Brad Walsh, Ph.D.

For more information: www.minomic.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...